Inhibitory action of methadone and its metabolites on erg-mediated K+ current in GH3 pituitary tumor cells

Toxicology

Volumn 280, Issue 1-2, 2011, Pages 1-9

  Huang, Mei Han ^a   Shen, Ai Yu ^a   Wang, Trey Shy ^a   Wu, Hui Ming ^a   Kang, Ya Fei ^a   Chen, Chia Tai ^a   Hsu, Tai I ^b   Chen, Bing Shuo ^b,c   Wu, Sheng Nan ^b  

^a FOOYIN UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Adverse effects; Erg Mediated K+ current; GH3 Pituitary tumor cell; Hyperprolactinemia; Methadone

Indexed keywords

2 ETHYL 1,5 DIMETHYL 3,3 DIPHENYLPYRROLINIUM PERCHOLARATE; 2 ETHYL 5 METHYL 3,3 DIPNEHYL 1 PYRROLINE; BUCLADESINE; CALCIUM ION; DRUG METABOLITE; DYNORPHIN[1-13]; METHADONE; NALOXONE; POTASSIUM CHANNEL HERG; POTASSIUM ION; RISPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN GH3; CONTROLLED STUDY; DISSOCIATION CONSTANT; ELECTRIC POTENTIAL; HYPERPOLARIZATION; IC 50; INHIBITION KINETICS; ION CURRENT; POTASSIUM CURRENT; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; ETHER-A-GO-GO POTASSIUM CHANNELS; METHADONE; NALOXONE; NARCOTICS; NEURONS; PITUITARY NEOPLASMS; PROLACTIN; PYRROLIDINES; RATS; RISPERIDONE;

EID: 78650519820     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.10.010     Document Type: Article

References (44)

1. Andrews C.M., Krantz M.J., Wedam E.F., Marcuson M.J., Capacchione J.F., Haigney M.C. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol. J. 2009, 16:210-217.
2. Bart G., Borg L., Schluger J.H., Green M., Ho A., Kreek M.J. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J. Pharmacol. Exp. Ther. 2003, 306:581-587.
3. Bart G., Schluger J.H., Borg L., Ho A., Bidlack J.M., Kreck M.J. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?. Neuropsychopharmacology 2005, 30:2254-2262.
4. Beck O., Boreus L., Lafolie P., Jacobsson G. Chiral analysis of methadone in plasma by high-performance liquid chromatography. J. Chromatogr. 1991, 570:198-202.
5. Bell J.R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009, 104:73-77.
6. Bennett J., Whale R. Galactorrhoea may be associated with methadone use. Br. Med. J. 2006, 332:1071.
7. Bermejo A.M., Lucas A.C., Tabernero M.J. Saliva/plasma ratio of methadone and EDDP. J. Anal. Toxicol. 2000, 24:70-72.
8. Borgland S.L., Connor M., Osborne P.B., Furness J.B., Christie M.J. Profiles for G protein activation, rapid desensitization, and endocytosis of Mu-opioid receptors. J. Biol. Chem. 2003, 278:18776-18784.
9. Chikhi-Chorfi N., Pham-Huy C., Galons H., Manuel N., Lowenstein W., Warnet J.M., Claude J.R. Rapid determination of methadone and its major metabolite in biological fluids by gas-liquid chromatography with thermionic detection for maintenance treatment of opiate addicts. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 718:278-284.
10. Chugh S.S., Socoteanu C., Reinier K., Waltz J., Jui J., Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am. J. Med. 2008, 121:66-71.
11. Eap C.B., Bourquin M., Martin J.J., Spagnoli J., Livoti S., Powell K., Baumann P., Deglon J.J. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 2000, 61:47-54.
12. Fanoe S., Jesen G.B., Siogren P., Korsgaard M.P., Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br. J. Clin. Pharmacol. 2009, 67:172-179.
13. Fonseca F., Marti-Almor J., Pastor A., Cladellas M., Farre M., de la Torre R., Torrens M. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. 2009, 99:327-332.
14. Furlan F., Taccola G., Grandolfo M., Guasti L., Arcangeli A., Nistri A., Ballerini L. ERG conductance expression modulates the excitability of ventral horn GABAergic interneurons that control rhythmic oscillations in the developing mouse spinal cord. J. Neurosci. 2007, 27:919-928.
15. Gianfrancesco F.D., Pandina G., Mahmoud R., Wu J., Wang R.H. Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. Ann. Gen. Psychiatry 2009, 8:5.
16. Hardman R.M., Forsythe I.D. Ether-à-go-go related gene K+ channels (ERG) contribute to threshold excitability of mouse auditory brainstem neurons. J. Physiol. 2009, 587:2487-2497.
17. He L., Kim J., Ou C., McFadden W., van Rijn R.M., Whistler J.L. Methadone antinociception is dependent on peripheral opioid receptors. J. Pain 2009, 10:369-379.
18. Horrigan F.T., Gilly W.F. Methadone block of K+ current in squid giant fiber lobe neurons. J. Gen. Physiol. 1996, 107:243-260.
19. Jiang Y.N., Li Y.H., Ke M.W., Tseng T.Y., Tang Y.B., Huang M.C., Cheng W.T., Ju Y.T. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis. Cancer Cell Int. 2007, 7:1.
20. Kanasaki H., Fukunaga K., Takahashi K., Miyazaki K., Miyamoto E. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol. Reprod. 2000, 62:1486-1494.
21. Katchman A.N., Koerner J., Tosala T., Woosley R.L., Ebert S.N. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 2006, 316:1098-1106.
22. + currents. J. Pharmacol. Exp. Ther. 2002, 303:688-694.
23. Kinon B.J., Ahl J., Liu-Seifert H., Maguire G.A. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006, 31:577-588.
24. Kornick C.A., Kilborn M.J., Santiago-Palma J., Schulman G., Thaler H.T., Keefe D.L., Katchman A.N., Pezzullo J.C., Ebert S.N., Woosley R.L., Payne R., Manfredi P.L. QTc interval prolongation associated with intravenous methadone. Pain 2003, 105:499-506.
25. Lin C., Somberg T., Molnar J., Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2010, 113:59-65.
26. Lin M.W., Wang Y.J., Liu S.I., Lin A.A., Lo Y.C., Wu S.N. Characterization of aconitine-induced block of delayed rectifier K+ current in differentiated NG108-15 neuronal cells. Neuropharmacology 2008, 54:912-923.
27. Liu Y.C., Wu S.N. Block of erg current by linoleoylamide, a sleep-inducing agent, in pituitary GH3 cells. Eur. J. Pharmacol. 2003, 458:37-47.
28. Nair M.K., Patel K., Starer P.J. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient. Addiction 2008, 103:2062-2064.
29. Ower K., Morley-Forster P., Moulin D. Fluctuating QTc interval in an asymptomatic patients treated with methadone for chronic pain. J. Opioid Manage. 2005, 1:73-76.
30. Pearson E.C., Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol. Drug Saf. 2005, 14:747-753.
31. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26:119-124.
32. Schledermann W., Wulfsen I., Schwarz J.R., Bauer C.K. Modulation of rat erg1, erg2, erg3, and HERG K+ currents by thyrotropin-releasing hormone in anterior pituitary cells via the native signal cascade. J. Physiol. 2001, 532:143-163.
33. Schwarz J.R., Bauer C.K. Functions of erg K+ channels in excitable cells. J. Cell. Mol. Med. 2004, 8:22-30.
34. Soldovieri M.V., Miceli F., Taglialatela M. Cardiotoxic effects of antihistamines: from basic to clinics (...and back). Chem. Res. Toxicol. 2008, 21:997-1004.
35. Spitzner M., Ousingsawat J., Scheidt K., Kunzelmann K., Schreiber R. Voltage-gated K+ channels support proliferation of colonic carcinoma cells. FASEB J. 2007, 21:35-44.
36. Sportert F., Pragst F. Determination of methadone and its metabolites EDDP and EMDP in human hair by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J. Chromatogr. B: Biomed. Sci. Appl. 2000, 746:255-264.
37. Sung R.J., Kuo C.T., Wu S.N., Lai W.T., Luqman N., Chan N.Y. Sudden cardiac death syndrome: age, gender, ethnicity, and genetics. Acta Cardiol. Sin. 2008, 24:65-74.
38. Szarfman A., Tonning J.M., Levine J.G., Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006, 26:748-758.
39. Tomura H., Okajima F., Kondo Y. Enkephalin induces Ca2+ mobilization in single cells of bradykinin-sensitized differentiated neuroblastoma hybridoma (NG108-15) cells. Neurosci. Lett. 1992, 148:93-96.
40. Trafton J.A., Ramani A. Methadone: a new old drug with promises and pitfalls. Curr. Pain Headache Rep. 2009, 13:24-30.
41. Wang H., Zhang Y., Cao L., Han H., Wang J., Yang B., Nattel S., Wang Z. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res. 2002, 62:4843-4848.
42. Wu S.N., Jan C.R., Li H.F., Chiang H.T. Characterization of inhibition by risperidone of the inwardly rectifying K+ current in pituitary GH3 cells. Neuropsychopharmacology 2000, 23:676-689.
43. Wu S.N., Lo Y.K., Kuo B.I., Chiang H.T. Ceramide inhibits the inwardly rectifying potassium current in GH3 lactotrophs. Endocrinology 2001, 142:4785-4794.
44. Wu S.N., Wu Y.H., Chen B.S., Lo Y.C., Liu Y.C. Underlying mechanism of actions of tefluthrin, a pyrethroid insecticide, on voltage-gated ion currents and on action currents in pituitary tumor (GH3) cells and GnRH-secreting (GT1-7) neurons. Toxicology 2009, 258:70-77.